The ability to provide safe and effective pharmacotherapy during obstetric complications, such as preterm labor or postpartum hemorrhage, is hampered by the systemic toxicity of therapeutic agents leading to adverse side effects in the mother and fetus. Development of novel strategies to target tocolytic and uterotonic agents specifically to uterine myocytes would improve therapeutic efficacy while minimizing the risk of side effects. Ligand-targeted liposomes have emerged as a reliable and versatile platform for targeted drug delivery to specific cell types, tissues or organs. OBJECTIVE: Our objective was to develop a targeted drug delivery system for the uterus utilizing an immunoliposome platform targeting the oxytocin receptor. STUDY DESIGN: We conjugated liposomes to an antibody that recognizes an extracellular domain of the oxytocin receptor. We then examined the ability of oxytocin receptoretargeted liposomes to deliver contraction-blocking (nifedipine, salbutamol and rolipram) or contractionenhancing (dofetilide) agents to strips of spontaneously contracting myometrial tissue in vitro (human and mouse). We evaluated the ability of oxytocin receptoretargeted liposomes to localize to uterine tissue in vivo, and assessed if targeted liposomes loaded with indomethacin were capable of preventing lipopolysaccharide-induced preterm birth in mice. RESULTS: Oxytocin receptoretargeted liposomes loaded with nifedipine, salbutamol or rolipram consistently abolished human myometrial contractions in vitro, while oxytocin receptoretargeted liposomes loaded with dofetilide increased contraction duration. Nontargeted control liposomes loaded with these agents had no effect. Similar results were observed in mouse uterine strips. Following in vivo administration to pregnant mice, oxytocin receptoretargeted liposomes localized specifically to the uterine horns and mammary tissue. Targeting increased localization to the uterus 7-fold. Localization was not detected in the maternal brain or fetus. Targeted and nontargeted liposomes also localized to the liver. Oxytocin receptoretargeted liposomes loaded with indomethacin were effective in reducing rates of preterm birth in mice, whereas nontargeted liposomes loaded with indomethacin had no effect.
Introduction
Complications arising from preterm birth (PTB) are the leading cause of death among children age <5 years, accounting for nearly 1 million deaths in 2013, 1 while postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide, accounting for up to 27.1% of maternal deaths. 2 Given that both can arise from dysregulation of uterine contractility, the need exists for safe and effective clinical interventions capable of modifying myometrial contractions to improve treatment of women in preterm labor, to induce or facilitate labor and to prevent or treat PPH, without adverse off-target effects on either the mother or fetus.
When a woman presents with preterm labor, attempts are often made to halt contractions by administering tocolytics that inhibit or block components of the contraction cascade. A recent study proposed that "the ideal tocolytic agent should be myometrium-specific, easy to administer, inexpensive, effective in preventing PTB and improve neonatal outcomes, with few maternal, fetal, and neonatal side effects, and without longterm adverse effects." 3 Standard therapy varies from country to country, but tocolysis may involve the administration of calcium channel blockers, such as nifedipine (NIF); b 2 -adrenergic receptor agonists, such as salbutamol (SAL); an oxytocin receptor (OTR) antagonist, such as atosiban; or a prostaglandin synthetase inhibitor, such as indomethacin (IND). [4] [5] [6] [7] [8] [9] Unfortunately, the systemic administration of these therapies and lack of specificity means that large doses need to be administered to achieve a therapeutic effect at the target tissue, the myometrium. Maternal side effects of b 2 -adrenergic receptor agonists include tremors, heart palpitations, and tachycardia, as well as myocardial ischemia and pulmonary edema. 8, [10] [11] [12] NIF has been associated with fewer side effects, however approximately 1% of women experience a severe side effect and a further 1% experience mild adverse side effects. 13 Atosiban is associated with the lowest side effect risk but the efficacy of this agent is disputed.
Usefulness of IND is limited by fetal side effects, such as premature closure of the ductus arteriosus. [16] [17] [18] Achieving targeted drug delivery to the myometrium would reduce the quantity of drug required to achieve therapeutic efficacy, reduce the likelihood of maternal and fetal side effects, and would therefore represent a significant advancement for maternal-fetal medicine.
12, [19] [20] [21] Targeted liposomes have emerged as a platform for achieving the delivery of drugs to specific tissues. Liposomes are artificial vesicles that range in size from 50-1000 nm, and are composed of !1 phospholipid bilayers. 22, 23 Liposomes are able to encapsulate both lipophilic and/or hydrophilic drugs, and are nontoxic and biodegradable with minimal immunogenicity. 21, 24, 25 Liposomal encapsulation improves the pharmacokinetics of drugs, particularly if the liposome surface is PEGylated, which reduces uptake by the reticuloendothelial system and prolongs half-life. 26 This has led to the development of liposomal-based preparations of various agents, including doxorubicin, amphotericin B, daunorubicin, and verteporfin. 27 Ligand-targeted liposomes offer the potential for site-specific delivery of drugs to designated cell types or organs in vivo that selectively express specific cell surface cognate receptors. 26 Although many types of targeting molecules are available, such as peptides/ proteins and carbohydrates, the coupling of antibodies to the liposome surface to create immunoliposomes has many advantages. One advantage of using antibodies is their stability and higher binding avidity because of the presence of dual binding sites. 26 For example, liposomes coated with antibodies to intercellular adhesion molecule (ICAM)-1 have been developed for the treatment of inflammatory diseases. 28 Administration of ICAM-1-targeted immunoliposomes loaded with an analgesic agent demonstrated specific localization and therapeutic efficacy exclusively in peripheral inflammatory tissue. All control groups (free drug solution, empty nontargeted liposomes, drug-loaded nontargeted liposomes, and empty ICAM-1-targeted immunoliposomes) showed no significant therapeutic response. 29 The aim of this study was to develop a means of targeting therapeutic agents to uterine myometrial tissue, to allow therapeutic modification of myometrial contractions in obstetric settings, such as preterm labor, labor induction, and PPH. The expression of the OTR is significantly up-regulated in myometrial cells approaching term. 30, 31 Here we report the development of OTR-targeted PEGylated immunoliposomes loaded with traditional tocolytics, such as NIF and SAL, as well as rolipram (ROL), a phosphodiesterase (PDE)4 inhibitor and potent inhibitor of myometrial contractions. [32] [33] [34] Moreover, we report enhancement of human myometrial contraction duration in vitro through liposomal delivery of dofetilide (DOF), a hERG channel blocker that increases myometrial contraction duration, 35, 36 demonstrating that this delivery platform can be used to either inhibit or enhance contractions in human myometrial tissue. We demonstrate that intravenously (IV) administered OTRtargeted liposomes localize specifically to the uterine tissue of pregnant mice in vivo. Finally, using an inflammatory mouse model of PTB (lipopolysaccharide [LPS] administration), we show that OTR-targeted liposomes loaded with IND are effective in preventing PTB, while IND-loaded nontargeted liposomes have no effect.
Materials and Methods

Myometrial tissue acquisition
Human studies These studies were performed in Newcastle, Australia, and were approved by the Hunter and New England Area Human Research Ethics Committee, adhering to guidelines of the University of Newcastle and John Hunter Hospital, Newcastle, Australia (02/06/12/3.13). All participants gave informed written consent. Collection of myometrial samples (5 Â 5 Â 10 mm) occurred from the lower uterine segment of term singleton pregnancies. All women were examined clinically, and those with signs of infection were excluded. Women were undergoing term elective cesarean delivery and were not in labor (NIL); the clinical indications for elective NIL cesarean delivery were previous cesarean delivery or previous third-/fourth-degree tear. All participants ranged from 37-40 completed weeks of gestation. Following delivery of the placenta, all women immediately received 5 U of oxytocin (Syntocinon) into an IV line, which was administered as standard care. Myometrial biopsies were excised 3-5 minutes after oxytocin administration, thus all samples were briefly exposed to oxytocin. After biopsy, myometrial samples were dissected from connective tissue and washed in ice-cold physiological saline.
Mouse in vitro studies
Mouse uterine horns were dissected from pregnant CD1 Swiss mice (8-10 weeks of age) at term gestation prior to the onset of labor (fetal gestation day [GA] 18). Mouse studies were approved by the University of Newcastle Animal Ethics Committee (A-2014-400/A-2014-429). All mice were housed under SPF/PC2 conditions under a 12-hour light-day cycle and had food and water available ad libitum.
Liposome manufacture
Liposomes containing NIF, SAL, ROL, DOF (each at approximately 4 mg/mL), or IND (approximately 5.5 mg/mL), as determined by high-performance liquid chromatography, were manufactured as previously outlined. 28 Liposomes were composed of 1,2-distearoyl-sn-glycero-2-phosphocholine (DSPC) and cholesterol in a molar ratio of 2:1, and contained 1,2-distearoyl-sn-glycero-3-phospho 0 ,3 0 -tetramethylindocarbocyanine perchlorate (DiI) for fluorescent detection. Unconjugated antibody and nonencapsulated drug was removed by centrifugal filtration of the liposomes through a 100-kd molecular weight filter (Amicon Ultra-15). Amicon Ultra-15 filters were washed with Milli-Q H 2 O before 500 mL of liposome suspension was loaded into the filter reservoir. Liposomes were diluted with 5 mL of sterile 0.9% saline and centrifuged at 4000 x g until retentate volume was <250 mL. Liposomes were then resuspended in a further 5 mL of 0.9% saline and centrifuged until retentate volume was <250 mL. Filtered liposomes were then collected, transferred to a fresh Eppendorf tube, and redispersed to an original volume of 500 mL.
The size distribution of the liposomal dispersion was determined by dynamic laser light scattering (Zetasizer Nano S, ATA Scientific). Encapsulation efficiency was determined by disrupting the vesicles with ethanol and evaluating drug concentration using high-performance liquid chromatography. Quantification of the amount of antibody associated with liposomes was determined using the CBQCA protein assay (ThermoFisher Scientific Inc, Waltham, MA), using bovine serum albumin for the preparation of the standard curve.
Myometrial contractility studies
Myometrial strips were set up as previously described. 37 Briefly, NIL human myometrial samples, or uterine horns obtained from pregnant CD1 Swiss mice, were dissected into strips (10 Â 2 Â 2 mm) and suspended in organ baths containing 30 force transducer (Grass Instruments, Quincy, MA) and 1g passive tension applied (1g was calibrated to equal 1 V). PSS was replaced 5 times during the first hour, with strips retensioned to 1g passive tension following each wash. Thereafter strips were maintained at 37 C until spontaneous rhythmic contractions developed. Data were digitized using a MacLab/8E data-acquisition system and contraction status visualized in real time using Chart software (ADInstruments, Dunedin, New Zealand). For each strip a contraction baseline was acquired to serve as reference. 38 To administer liposome treatments, 600 mL of PSS buffer was carefully extracted from an organ bath and transferred to an Eppendorf tube. The appropriate volume of liposome preparation (mixed by inversion) was pipetted into the PSS to predilute the liposomes. The total volume of prediluted liposomes (600 mL PSS þ liposomes) was then carefully reinjected back into the appropriate organ bath. Final concentrations of each drug were: NIF 7.7 mmol/L, SAL 9.25 mmol/L, ROL 19.4 mmol/L, and DOF 3.0 mmol/L. Doses were based on prior investigations of the nonencapsulated drug (in vitro contraction assays using human myometrium). Where treated tissue was not washed, tissue strips remained in the presence of the liposomes for the duration of the assay. Where washout studies were performed, organ baths were twice drained of buffer and refilled with 37 C PSS. Human tissue strips were washed after 1 hour and 25 minutes whereas mouse tissue strips were washed after 15 minutes.
Tension generated by tissue strips is indicated in the results and representative contraction traces. The effect of treatments is interpreted relative to the pretreatment contraction baseline, which consisted of !3 contractions of consistent frequency and amplitude.
In vivo biodistribution study
Timed-mated CD1 Swiss pregnant mice were injected with drug-free, DiI-labeled preparations of either nontargeted or OTR-targeted liposomes on fetal GA 17 Schematic of oxytocin receptoretargeted liposome structure
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PTB study
Time-mated pregnant CD1 Swiss mice were administered 0.7 mg/g LPS from Escherichia coli (0111:B4) (SigmaAldrich) via intraperitoneal (IP) injection at 12:00 PM on GA 15 (1-time injection). LPS dose had been previously optimized to result in PTB rates of 50-70%. Total IP injection volume was 150 mL in saline.
At 4:00 PM on GA 15, mice began receiving daily IV injections of IND freedrug or liposomal preparations according to assigned treatment groups. Treatment groups are indicated in Table 1 . Total IV injection volume was 150 mL. Mice were monitored for onset of labor every 6 hours. Treatments were repeated daily at 4:00 PM until all mice labored. Term gestation was 19-22 days. Mice that labored within 48 hours of receiving LPS (GA 17) were deemed to have labored preterm.
Statistical analyses
For contraction traces, LabChart software (ADInstruments) was used to determine the area under the curve (AUC) (g tension Â seconds) for the 30 minutes prior to treatment (pretreatment) and 30 minutes after treatment (posttreatment). AUC before and after treatment was compared by 2-tailed paired t test (GraphPad Prism).
For DOF studies, contraction plateau duration (seconds) was determined for 4 contractions pretreatment and posttreatment using LabChart software. Plateau duration was determined as the time between the point of highest amplitude and point where contraction force declined sharply. Contraction duration data were obtained for 3 individual tissues (n ¼ 3 women). Pretreatment and posttreatment measurements (n ¼ 12 each) were compared by 2-tailed unpaired t test.
Average radiance (p/s/cm 2 /sr) was determined for each organ of interest using Living Image software (v2.5).
Where fluorescence was detected, regions of interest were applied automatically (contour). Where detection was low or absent, regions of interest were specified manually (circles or squares) to tightly encompass the tissue being analyzed. Data were tested for normality by the Shapiro-Wilk normality test (GraphPad Prism). Average radiance for each organ/tissue was compared between treatment groups (n ¼ 4 animals per group) by 1-way analysis of variance (ANOVA) with multiple comparisons (Holm-Sidak) (GraphPad Prism).
For 
Consumables and reagents
Mice were supplied by the University of Newcastle Animal Support Unit. NIF (catalog no. 1075), SAL hemisulfate (catalog no. 0634), ROL (catalog no. 0905), and DOF (catalog no. 3757) were purchased from Tocris (Bristol, United Kingdom). IND (catalog no. L2630) was purchased from Sigma-Aldrich Pty Ltd (Sydney, Australia). Anti-OTR antibody (ab115664) was purchased from Abcam. Other miscellaneous reagents were purchased from Sigma-Aldrich Pty Ltd and ThermoFisher Scientific Inc.
Results
Characteristics of the liposomal delivery system
OTR-targeted PEGylated immunoliposomes had a mean particle size of 197 AE 6.8 nm with a polydispersity index of mg and a phospholipid concentration of 2.03 Â 10 e5 mol this equates to a conjugation efficiency of >99%. The liposomes have a neutral net charge and a drug loading efficiency of >95%, which equates to w4 mg/mL of drug encapsulated/mL of liposome suspension composed of 16 mg DSPC and 4 mg cholesterol (molar ratio 2:1). In vitro dialysis studies have demonstrated highly stable vesicles upon dilution in an aqueous phase (PBS pH 7.4) and in serum (50% FCS) at 37 C (data not included).
Human myometrial contractility
Contraction bioassays were performed to assess whether targeted liposomes were capable of delivering encapsulated therapeutic agents to modulate spontaneous human uterine contractions in vitro. Treating the uterine strips with OTR-targeted liposomes that contained no therapeutic agent (n ¼ 3) (Figure 2 , Ai) had no effect on myometrial contractility in that AUC was not affected (P ¼ . (Figure 2, Civ) . Similar results were observed when ROL was encapsulated in nontargeted and OTR-targeted liposomes (Figure 4) .
To demonstrate that our OTRtargeted liposomes are capable of functioning as a drug delivery system for different obstetric applications, such as treating PPH, liposomes were prepared that contained the hERG channel blocker, DOF. When administered to human myometrial tissue, DOF increases the contraction duration and reduces contraction frequency by delaying repolarization of the myocyte membrane. (Figure 3 , Bii). Increased contraction plateau duration is consistent with our previous report of DOF action on human myometrium. 36 These results demonstrate that a single delivery system, OTR-targeted liposomes, can be utilized to deliver either contractionblocking or contraction-promoting therapeutics to uterine myocytes.
The effect of nontargeted and OTRtargeted DOF-loaded liposomes on AUC was analyzed. Neither treatment significantly affected AUC (data not shown).
Effect of targeted liposomes is reversible
To demonstrate that the effects on contractility were due to pharmacological actions of the drugs and not the result of toxic effects of OTR-targeted liposomes, washout experiments were performed. ROL is a reversible inhibitor of PDE4 that induces myometrial relaxation. 
Mouse myometrial contractility
Prior to commencing mouse in vivo studies, we confirmed that liposomes were effective in delivering therapeutic agents to mouse uterine tissue in vitro. Results observed in the mouse were consistent with human myometrial contractility studies. OTR-targeted, drug-free liposomes (a control preparation) had no effect on mouse uterine contractions ( Figure 5, A) (n ¼ 3) . 
Liposome biodistribution
We examined the biodistribution of DiIlabeled nontargeted (naked) and OTRtargeted liposomes that occurred in vivo. Pregnant mice were injected with liposomes approaching term (GA 17 and 18) then sacrificed shortly after labor (GA 19) (17-19 hours after injection). Whole organs (liver, brain, heart, kidney, lung, mammary tissue, and uterus) were placed on Petri dishes, along with a euthanized neonate, and imaged. The arrangement of tissues ( Figure 6 , A) was kept consistent when imaging tissues from different mice. DiI does not readily exchange out of liposomes into cell membranes or other lipid-containing structures, and therefore is an appropriate marker to assess the biodistribution of liposomes.
Fluorescence detection (p/s/cm 2 /sr) of nontargeted liposomes injected into pregnant mice consistently revealed liposome accumulation in the liver, which is the site of liposome clearance from the blood stream and metabolism. 41 Accumulation of nontargeted liposomes was not detected in the brain, heart, kidney, lung, mammary tissue, or uterus nor in the neonates (n ¼ 4 each) ( Figure 6B ; animals 1 -4). Organs isolated from mice injected with OTRtargeted liposomes showed accumulation of the OTR-targeted liposomes in the uterus and the mammary glands. As expected, there were also high levels of liposome localization in the liver. OTRtargeted liposome accumulation was not detected in the brain, heart, kidney, DiI fluorescence was quantified for each organ ( (Figure 6 , C). On average this equaled a 7-fold increase in uterine localization. Furthermore, the level of OTR-targeted liposome localization in the uterus was significantly greater than that of brain (P ¼ .0002), lung (P ¼ .0003), kidney (P ¼ .0005), heart (P < .0001), and neonate (P < .0001) (Figure 6, C) . For both nontargeted and OTR-targeted liposomes, accumulation in the liver was significantly greater than all other organs examined (P < .0001), however there was no difference in liposome accumulation in the liver between nontargeted and OTR-targeted liposomes (P >.9999; nontargeted ¼ 7.90 Â 10 8 AE 9.15 Â 10 7 ; OTR-targeted ¼ 7.37 Â 10 8 AE 9.05 Â 10 7 ) (Figure 6 , C).
Preventing PTB
We used an LPS model of PTB to assess whether targeted liposomes could be used to administer IND for the prevention of LPS-induced PTB in mice. Nontargeted and OTR-targeted liposomes loaded with 5.5 mg/mL IND were compared against IND administered as free drug (1.0 or 2.0 mg/kg/d). Observed PTB rates are indicated in Table 3 . The c 2 analyses were performed. PTB rates in control mice (group 1) and the LPS control group (group 2) were 0 (n ¼ 12) and 67% (n ¼ 18), respectively. At 2.0 mg/kg/d, IND administered as free drug significantly reduced rates of PTB from 67% down to 31% (group 2 [n ¼ 18] vs group 4 [n ¼ 13]; P ¼ .0484) (Figure 7, A) . PTB rate for OTR-targeted, drug-free control liposomes (group 5) was 56% (n ¼ 16), and was not different to PTB rate observed for LPS control animals (group 2) (P ¼ .532). IND administered at 2.0 mg/kg/d via nontargeted liposomes (group 6) (n ¼ 12) had no effect as the observed PTB rate of 58% was not significantly different from PTB rates for LPS control animals (group 2) (P ¼.643) or animals treated with OTR-targeted, drug-free liposomes (group 5) (P ¼ .91) (Figure 7, A) .
IND administered at 2.0 mg/kg/d via OTR-targeted liposomes (group 7) (n ¼ 11) resulted in a PTB rate of 18%, which was a significant reduction compared to the PTB rate of 67% for the LPS control animals (group 2) (P ¼ .0112) (Figure 7 , A). Furthermore, PTB rate for 2.0 mg/ kg/d IND administered via OTRtargeted liposomes was significantly reduced compared to the same dose administered by nontargeted liposomes (group 6) (P ¼ .048). No significant difference was observed between 2.0 mg/ kg/d IND administered as free drug compared to when administered via OTR-targeted liposomes (group 4 vs group 7; P ¼ .4780) (Figure 7, A) .
The time between LPS injection and labor was calculated for each animal (average AE SEM shown in Table 3 ). Analysis of the normalized data showed that IP administration of LPS (0.7 mg/g) significantly advanced the time of labor, compared to control animals (group 1 vs group 2; P ¼ .0017) (Figure 7, B) . IND administered as free drug at 1.0 and 2.0 mg/kg/d dose-dependently increased the average time between LPS injection and labor (77.5 AE 14.1 and 86.6 AE 12.7 hours, respectively) compared to the LPS control (50.8 AE 8.9 hours), however neither dose reached statistical significance (group 2 vs group 3; P ¼ .53, and group 2 vs group 4; P ¼ .08) (Figure 7,  B) . OTR-targeted, drug-free liposomes had no effect on time between LPS injection and labor, compared to LPS Original Research OBSTETRICS ajog.org control animals (group 2 vs group 5; P ¼ .92). A total of 2.0 mg/kg/d IND administered via nontargeted liposomes had no significant effect on the time between LPS injection and labor (group 2 vs group 6; P ¼ .99), however, when administered via OTR-targeted liposomes, time between LPS injection and labor was significantly increased (group 2 vs group 7; P ¼.0048). The time between LPS injection and labor was significantly different between 2.0 mg/kg/d IND delivered via nontargeted liposomes compared to OTR-targeted liposomes (group 6 vs group 7; P ¼ .0438).
Number of live pups was recorded for term deliveries (no viable pups arose from preterm deliveries). Data were normally distributed (Shapiro-Wilk normality test) and analyzed by 1-way ANOVA with multiple comparisons (Tukey). There was no significant difference in the number of live pups from term deliveries in the different groups (Figure 7, C) .
Comment
Principal findings
OTRs are expressed at low levels on various tissues toward the end of pregnancy, including the brain and 42 Expression in the pregnant uterus however is high approaching term, 30, 31 indicating that the OTR is an excellent candidate for the development of a targeted drug delivery system for the uterus. This study represents an initial analysis of OTR-targeted liposomes as a drug delivery system, and demonstrates that: 
Clinical significance
Many current tocolytics have been associated with adverse effects on the and on the fetus (NIF, IND) [16] [17] [18] 45, 46 or have no evident effect on prolongation of pregnancy (atosiban). 14, 15 NIF is capable of providing some clinical benefit, with a systematic review and meta-analysis indicating a significant reduction in the risk of delivery within 7 days of initiation of NIF treatment. 3 However, the high doses required to achieve relaxation of the myometrium increases the risk of adverse systemic effects. 45 Here we have demonstrated in mice that IND encapsulated inside OTR-targeted liposomes was effective in reducing rates of LPS-induced PTB, whereas nontargeted IND-loaded liposomes were not. These results, in conjunction with our biodistribution studies, suggest that OTR targeting confers upon liposomes the ability to target therapeutics to the uterus. The clinical implications are that OTR-targeted liposomes may enable existing tocolytics, such The restricted biodistribution of OTR-targeted liposomes raises the possibility of introducing into clinical practice therapeutic agents that are known to be highly effective tocolytics, yet are known to have adverse off-target effects. One such group of candidates are the PDE4 inhibitors, such as ROL, which have been demonstrated to be highly effective in controlling inflammationdriven preterm delivery in mice. 53 Mounting evidence indicates that PTB in human beings is also an inflammation-driven event, and evidence that ROL is highly effective in abolishing spontaneous contractions in human myometrium 33 suggests that PDE4 inhibitors may be excellent cargo for OTR-targeted liposomes in the setting of preterm labor.
Clinical implications also include the prospect of encapsulating uterotonic agents, and here we demonstrate that possibility through the use of DOF. DOF is not a traditional uterotonic agent, but when administered via OTR-targeted liposomes DOF significantly increased the duration of human myometrial contractions in vitro, consistent with previous findings. 36 Targeted delivery of uterotonics may be useful to promote contractions, including during failure of labor to progress, expulsion of the placenta after labor, expulsion of retained products after miscarriage, or to control PPH. PPH is a leading cause of maternal mortality worldwide and is linked with major morbidities such as peripartum hysterectomy and massive transfusion. [54] [55] [56] First-line therapy for PPH is uterine massage and oxytocin administration, however rates of atonic PPH after oxytocin use are increasing in many developed countries. 57, 58 When refractory uterine atony occurs, secondline therapy may include administration of uterotonic agents such as methylergonovine and carboprost. Methylergonovine was recently identified as the more effective of the two, 59 however both agents could effectively be encapsulated in OTR-targeted liposomes. Evidence indicates that postreceptor contractile signaling pathways are maintained in oxytocin desensitized primary myocytes in vitro, 60 however oxytocin desensitization occurs, at least in part, by down-regulation of OTR protein levels. 61 Uterotonic-loaded liposomes targeted to the OTR may therefore be of reduced effectiveness in patients with prolonged exposure to oxytocin.
Future research
These data provide the first evidence that OTR-targeted liposomes are a drug delivery system that affords flexibility in delivery of different classes of therapeutic agents to human uterine tissue to modulate myometrial contractility. Furthermore, these data provide the first evidence that OTR-targeted liposomes can be used to administer therapeutic agents for the prevention of PTB in mice.
Further studies are necessary to determine the mechanism of OTRtargeted liposome uptake in myocytes, the quantitative biodistribution of therapeutic agents achieved in the uterus compared to other organs, and the rate of liposome clearance. Additional studies have been planned to determine whether the use of OTR-targeted liposomes to administer therapeutics for prevention of PTB is effective in reducing fetal side effects, such as premature closure of the ductus arteriosus in response to IND exposure in utero. n
